| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
70,779 |
58,058 |
$3.66M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
62,506 |
50,773 |
$1.44M |
| G0482 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed |
9,147 |
7,278 |
$688K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
4,520 |
4,101 |
$172K |
| 01992 |
|
1,478 |
1,174 |
$130K |
| 64483 |
|
997 |
791 |
$91K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
602 |
474 |
$54K |
| 99439 |
|
1,700 |
1,567 |
$41K |
| 99406 |
|
11,453 |
8,762 |
$37K |
| 99205 |
Prolong outpt/office vis |
348 |
282 |
$34K |
| 99490 |
Ccm add 20min |
2,289 |
2,004 |
$31K |
| G0483 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed |
534 |
386 |
$28K |
| 64479 |
|
140 |
114 |
$16K |
| 64484 |
|
380 |
266 |
$12K |
| 64493 |
|
141 |
113 |
$11K |
| 77003 |
|
756 |
562 |
$7K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
64 |
63 |
$7K |
| 82570 |
|
6,966 |
4,861 |
$6K |
| 01991 |
|
93 |
68 |
$6K |
| 64494 |
|
98 |
74 |
$5K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
92 |
85 |
$3K |
| 99487 |
Ccm add 20min |
124 |
118 |
$3K |
| 99489 |
Ccm add 20min |
124 |
118 |
$2K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
41 |
41 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
156 |
127 |
$2K |
| 99457 |
|
199 |
182 |
$1K |
| 72275 |
|
14 |
12 |
$1K |
| 99458 |
|
122 |
106 |
$1K |
| 20553 |
|
47 |
28 |
$731.59 |
| 64480 |
|
15 |
13 |
$612.10 |
| 99454 |
|
66 |
65 |
$524.99 |
| 77002 |
|
32 |
27 |
$436.73 |
| 99244 |
Office or other outpatient consultation, moderate to high complexity |
36 |
15 |
$360.39 |
| J3490 |
Unclassified drugs |
14 |
12 |
$346.24 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
169 |
128 |
$247.36 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
36 |
29 |
$136.39 |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
16 |
15 |
$136.04 |
| 99453 |
|
37 |
35 |
$99.58 |
| 99215 |
Prolong outpt/office vis |
23 |
18 |
$25.25 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
37 |
30 |
$8.13 |
| G9577 |
Patients prescribed opiates for longer than six weeks |
7,361 |
5,385 |
$0.00 |
| G9562 |
Patients who had a follow-up evaluation conducted at least every three months during opioid therapy |
1,158 |
940 |
$0.00 |
| G9561 |
Patients prescribed opiates for longer than six weeks |
59 |
44 |
$0.00 |
| G9578 |
Documentation of signed opioid treatment agreement at least once during opioid therapy |
178 |
147 |
$0.00 |
| G9584 |
Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy |
726 |
600 |
$0.00 |
| 99000 |
|
858 |
765 |
$0.00 |
| 1034F |
|
146 |
120 |
$0.00 |
| G9583 |
Patients prescribed opiates for longer than six weeks |
19 |
16 |
$0.00 |